Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Gains from Investment Securities: 2013-2024

Historic Gains from Investment Securities for Seres Therapeutics (MCRB) over the last 12 years, with Dec 2024 value amounting to $17.7 million.

  • Seres Therapeutics' Gains from Investment Securities rose 399.15% to $1.2 million in Q1 2025 from the same period last year, while for Mar 2025 it was $1.2 million, marking a year-over-year decrease of 52.68%. This contributed to the annual value of $17.7 million for FY2024, which is 19.38% up from last year.
  • As of FY2024, Seres Therapeutics' Gains from Investment Securities stood at $17.7 million, which was up 19.38% from $14.8 million recorded in FY2023.
  • In the past 5 years, Seres Therapeutics' Gains from Investment Securities ranged from a high of $17.7 million in FY2024 and a low of $10.0 million during FY2020.
  • Its 3-year average for Gains from Investment Securities is $15.8 million, with a median of $14.9 million in 2022.
  • In the last 5 years, Seres Therapeutics' Gains from Investment Securities rose by 29.72% in 2022 and then dropped by 0.64% in 2023.
  • Over the past 5 years, Seres Therapeutics' Gains from Investment Securities (Yearly) stood at $10.0 million in 2020, then rose by 14.75% to $11.5 million in 2021, then increased by 29.72% to $14.9 million in 2022, then decreased by 0.64% to $14.8 million in 2023, then increased by 19.38% to $17.7 million in 2024.